r/HUMACYTE

Is this good that it’s up or is it going to dump again. I’m not too good with research.

Wow, this is actually good PR. It surely is hard to publish in Lancet.

The selling from Fresnius is mostly over.

The bulk of the planned reduction is complete, and the remaining amount under the 10b5-1 plan is relatively small. Selling could continue in limited amounts through late October 2026

August 10, 2026: 197,500 shares at a weighted average of $0.7249 per share (proceeds $143,167.75)

August 11, 2026: 220,000 shares at a weighted average of $0.7213 per share (proceeds $158,686.00)

August 12, 2026: 680,000 shares at a weighted average of $0.6389 per share (proceeds $434,452.00)

August 13, 2026: 1,300,000 shares at a weighted average of $0.5973 per share (proceeds $776,490.00)

August 14, 2026: 1,300,000 shares at a weighted average of $0.5585 per share (proceeds $726,050.00)

August 17, 2026: 1,012,000 shares at a weighted average of $0.5547 per share (proceeds $541,104.83)

In Amendment No. 11, they reported selling a total of 4,709,500 shares between August 10 and August 17, 2026. That leaves roughly 290,500 shares still authorized under the plan.

From humacyte themselves: https://humacyte.gcs-web.com/news-releases/news-release-details/board-certified-vascular-and-endovascular-surgeon-performs-first

The moment this stock is living goes beyond terrible, but I went through the 13/F filings that were due around this period and...

~1M shares bought by HRT Financials RP

~1,3M shares bought by Charles Schwab

~2M shares bought by Millennium Management

~3,7M shares bought by Great Point Partners

~5M shares bought by Davidson Kempner Group

~1,5M shares bought by Citadel.

~6M shares bought by Alyeska.

And many, really many more. And I just highlighted some newly opened positions, there are many increases by large institutions, like Vanguard which reached 10M shares. Of course, there are sells too, but way less. This is institutional activity that would make any small cap stock skyrocket for months.

To be fair, many of these players, like Alyeska and Citadel, are known speculative investors, so they buy and sell within a year, not the kind of long term buyers one might hope for.

And yet, this is not an institutional ownership profile that reflects the current situation of both the company and the stock. Maybe they bought, as many did by what the filings report, around the end of June hoping to make quick bucks on the ER (gotta say, not really institutional behaviour). Or maybe they know something more.

I see many people on this sub with a high cost basis saying things such as:

"I'm going down with the ship" or "the stock price is very low, so there's no point in selling"

The problem is that you are most likely not going to get your money back at this point. As a result, you will significantly underperform the major indices.

The simple reason why is dilution. When a company raises money from investors, previous investors suffer as the share count rises.

Think about it like this:

In 2022, you bought HUMA at $5 with 103m shares outstanding ($515m market cap)

Today, HUMA is $0.60 with 270m shares outstanding ($162m market cap)

For the stock to reach your break-even cost of $5, the market cap as of today must be $1.35b (270m shares * $5 cost) with the share count remaining stable (most likely not going to happen).

This company burns roughly $20m each quarter and will need to raise capital later this year or early-to-mid 2027. Assuming they raise the equivalent amount as the last dilution event at $1, this would add another 57.5m shares (total now 328m), resulting in a higher break-even market cap of $1.64b.

For those of you underwater, please think about this deeply when they do another raise. It is pushing your cost higher and higher, even as the company executes, due to a severe need for more cash.

title

Based on the recent developments it is evident that Humacyte has really exhausted the ability to easily get cash by share dilution, especially if they get delisted.

What are your opinions about a theoretical acquisition, I would assume that a buyout would have a share price significantly above 1$? Their IPs would be worth a lot more in the hands of a better owner.

the incompetence lives on. Poor shareholders. fck Dale. Laura. an FDA, "breakthrough" product, can't even land a single whale investor?? instead just bleed shareholders with dilution? tf are the mgt doing, and not going out there to even just snake oil market Symvess to shady investors, heck Cathy, Jane St. or Gandhi for all i care just get us a massive cash inflow and im out.

https://preview.redd.it/3njx4id1pxih1.png?width=576&format=png&auto=webp&s=ee0023cafcac56b97796cbf8b29b957517f5d0ec

title

Not financial advice. Just one investor trying to explain why this ticker refuses to leave my head.

Most people who look at HUMA today look at the chart and stop right there: a share price languishing under $1.00 (~$0.65), a market cap compressed to ~$185M, past dilution, warrants, and ugly candles. The quintessential "troubled penny biotech" easily written off as "too risky" or "bagholder fuel."

But the deeper you dig into the fundamental reality in 2026, the harder it gets to reconcile that surface narrative with what is actually happening on the ground.

HUMA is not a slide-deck dream anymore. It already did the hardest part.

1. The Science is Validated and on the Market (Symvess)

They grow off-the-shelf human blood vessel replacements in bioreactors. Starting with donor cells, they grow a vessel on a scaffold, then wash out the cellular material to leave a neutral matrix. Once implanted, the patient's own cells colonize it, turning it into living tissue over time.

FDA clearance for extremity vascular trauma is already in hand. Symvess is actively used in civilian operating rooms and across military conflict zones (supported by the U.S. Military ECAT procurement channel).

When a patient faces limb loss:

Option A: Harvest the patient's own vein (takes critical time, not always available).

Option B: Use a synthetic plastic graft (disastrous infection rates in dirty trauma fields).

Option C (Symvess): Grab an off-the-shelf vessel that resists infection like a natural vein and transforms into living human tissue.

2. The Manufacturing Moat (LUNA200 / V012)

A common mistake is treating HUMA like an early-stage lab project.

In North Carolina, Humacyte operates a commercial-scale, automated manufacturing infrastructure (LUNA200 / V012) capable of producing tens of thousands of vessels annually with high gross margins. Replicating this facility—validated and inspected by the FDA—would cost any competitor a decade and hundreds of millions of dollars. That isn't speculative tech; it's a massive physical asset.

3. The Multi-Billion Dollar Dialysis Market (sBLA & TDAPA)

Trauma was just the on-ramp. The recurring revenue driver is AV access for end-stage renal disease (dialysis).

Phase 3 trial results demonstrated that Humacyte's vessel maintained longer usability than standard fistulas or synthetic grafts, with even greater superiority in high-risk subgroups (diabetic, obese, and female patients) where current options fail constantly.

The sBLA submission process is moving forward with the FDA. Upon approval, the TDAPA reimbursement pathway will open doors to major dialysis operators (DaVita, US Renal Care).

4. What Shifted in 2026: Financial & Strategic Catalysts

This is where the disconnect between the stock price and corporate reality becomes glaring:

100% Global Rights Reclaimed: In April 2026, Humacyte officially regained 100% of its ex-U.S. commercial rights from Fresenius. Humacyte now has a clean slate to negotiate new regional licensing partnerships.

The Saudi Arabia Joint-Venture: Active negotiations for a Saudi Arabian JV (featuring potential non-dilutive upfront cash and local infrastructure funding) remain a pivotal catalyst. A single international partnership deal would neutralize short-term liquidity risks.

Commercial Leadership Pivot: The team has added battle-tested commercial sales executives to accelerate adoption across hospital Value Analysis Committees (VACs).

Coronary Artery Bypass Graft (CABG): Human trials for small-diameter (3.5mm) heart bypass vessels are actively underway—opening a $2B+ total addressable market.

5. Short Interest & Sentiment Asymmetry

The stock remains heavily shorted (~30 million shares sold short). Wall Street has priced in perpetual dilution or imminent distress.

Yet while the ticker trades like a failing penny stock:

Vascular surgeons continue implanting the vessel in real-world cases.

Hospital procurement committees are onboarding the product under NTAP reimbursement.

International partnership discussions are maturing.

Thesis Summary

The primary risk today is no longer "Does the science work?" (the FDA and Phase 3 data answered that). The risk lies entirely in commercial execution speed and cash runway management prior to finalizing major non-dilutive partnerships.

If execution continues:

Trauma validates early commercial adoption.

Dialysis unlocks high-margin, recurring revenue.

The LUNA200 automated platform provides an insurmountable moat.

Any resolution of financial risk will force a rapid cover from 30+ million short shares.

The market currently prices Humacyte as an uncertain science project. The reality is a fully approved, industrialised regenerative medicine platform already saving lives, backed by a massive manufacturing moat and a second major launch in dialysis.

Do your own homework, read the SEC filings, review the balance sheet, and decide if this type of high-asymmetry biotech profile belongs in your portfolio.

Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the Company will release its financial results for the three months and six months ended June 30, 2026, on Wednesday, August 12, 2026. Management will host a webcast and conference call at 8:00 a.m. Eastern Time to provide a corporate and financial update.

https://investors.humacyte.com/news-releases/news-release-details/humacyte-announce-2026-second-quarter-financial-results-and